Novartis MS Pill Beats Older Drug in Clinical Trials
Novartis reports its oral drug remibrutinib successfully reduced relapses in multiple sclerosis patients during late-stage trials. The positive results boost hopes for the companys drug pipeline and potential blockbuster sales.
Xurve View
Insights:
Xurve View
NOVARTIS AG-REG said remibrutinib beat an older multiple sclerosis treatment in two late-stage trials, boosting peak sales expectations to $9 billion. The Swiss drugmaker's shares rose 4% following the announcement during Tuesday's trading session. The positive data provides a key pipeline boost as the company faces generic competition for its blockbuster heart-failure drug Entresto.
